Biodesix Inc. (BDSX), a diagnostic solutions company that achieved accelerating growth last year, is preparing to capitalize on that momentum in 2026.
The company's diagnostic tests are designed to help healthcare providers meaningfully improve lung disease diagnosis, treatment, and monitoring, as well as lower the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. It currently offers two tests that assess the risk of cancer in lung nodules and three tests that provide treatment guidance after a lung cancer diagnosis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com